Fig. 1From: Which severe COVID-19 patients could benefit from high dose dexamethasone? A Bayesian post-hoc reanalysis of the COVIDICUS randomized clinical trialCOVIDICUS Trial: Main trial outcome across the DXM randomized groups. Overall survival according to randomization (a) and posterior density of the hazard ratio (HR) of the 60-day mortality rate in the whole trial population based on a noninformative prior (b) or using either a sceptical or an enthusiastic prior (c)Back to article page